

OFFICIAL

AUG 24 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BUSSE *et al.*

Appl. No.: 09/675,650

Filed: September 29, 2000

For: PCA3 Messenger RNA Species in
Benign and Malignant Prostate
Tissues

Confirmation No.: 1706

Art Unit: 1642

Examiner: Yu, Misook

Atty. Docket: 1619.0080001/JAG/CMB

Supplemental Amendment and Reply Under 37 C.F.R. § 1.111(a)(2)

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Office Action ("OA") dated February 10, 2004 in connection with the above-identified patent application please consider the following Amendments and Remarks.

Applicant's representative thanks the Examiner for the courtesy of the telephone interview on August 23, 2004. As discussed in that interview, this Supplemental Amendment and Reply Under 37 C.F.R. § 1.111(a)(2) replaces the Amendment and Reply Under 37 C.F.R. § 1.111 filed on August 10, 2004. As also discussed in that interview, the Examiner will consider this Supplemental Amendment and Reply Under 37 C.F.R. § 1.111(a)(2) in response to the Office Action issued February 10, 2004.

Applicants submitted concurrently with the Amendment and Reply Under 37 C.F.R. § 1.111 filed on August 10, 2004 a Petition for Extension of Time for three months, to and including August 10, 2004, accompanied by the required fee. It is not believed that extensions of time or other fees are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

This Amendment and Reply is provided in the following format:

(A) Each section begins on a separate sheet;

BUSSE *et al.*
Appl. No. 09/675,650

- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
- in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.